Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2019-03-11 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
董事会议事规则（2019年3月）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors'. It details the internal rules, decision-making processes, meeting procedures, voting, and responsibilities of the board of directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It references company law, company articles, and governance practices. There is no financial data, audit information, or report publication mentioned. The content is focused on governance structure and board operations, which fits the definition of Governance Information (CGR). The document length is sufficient and it is not an announcement or certification but a substantive governance document.
2019-03-11 Chinese
2018年度独立董事述职报告（王红欣）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2018" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, supervision of company operations, and other governance-related activities during the year 2018. The content focuses on the independent director's duties, governance oversight, and compliance with laws and regulations. It is not a full annual report, audit report, or financial statement, nor is it an announcement or proxy solicitation. It is a detailed report on board/management information specifically from an independent director about their activities and governance role. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it is a substantive report, not just an announcement of a report, so it is not RPA or RNS.
2019-03-11 Chinese
2018年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2018 年年度报告全文" which translates to "2018 Annual Report Full Text" for Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data, business summary, management discussion and analysis, governance, and financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. There are no indications that this is merely an announcement or a certification. The content includes comprehensive financial figures, business operations, risk factors, and management commentary, all consistent with an official annual report filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2018
2019-03-11 Chinese
第四届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the approval of the 2018 Supervisory Board Work Report, the 2018 Annual Report and its summary, the 2018 profit distribution plan, internal control self-evaluation report, accounting policy changes, use of idle funds for bank wealth management products, guarantees for subsidiaries, and amendments to the Articles of Association. The document states that these reports and proposals will be submitted to the 2018 Annual General Meeting for approval. The document itself is a meeting resolution announcement and does not contain the full annual report or detailed financial statements but references where these can be found. The document length is 3827 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE, this document is an announcement of resolutions and reports rather than the reports themselves. This fits best with the category of Regulatory Filings (RNS), as it is a general regulatory announcement about supervisory board meeting resolutions and related company matters without the full report content.
2019-03-11 Chinese
2018年度独立董事述职报告（韩文君）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2018" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, supervision of internal controls and information disclosure, and other duties performed during the year 2018. The content focuses on governance, oversight, and the independent director's role rather than financial results or audit opinions. It is not an annual report, audit report, or earnings release. The document is a detailed report by a board member about their activities and governance role, which fits the category of Board/Management Information (MANG). The document length is 2822 characters, which is relatively short but contains substantive content about board activities and management oversight, not just an announcement or certification. Therefore, the best classification is MANG with high confidence.
2019-03-11 Chinese
第四届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 19th meeting of the 4th Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approvals of the 2018 annual general manager work report, 2018 board work report, 2018 annual report and its summary, profit distribution plan, appointment of a new deputy general manager, renewal of audit firm, internal control self-assessment report, accounting policy changes, credit facility applications, investment in bank wealth management products, guarantees for subsidiaries, amendments to company articles and meeting rules, and the proposal to convene the 2018 annual shareholders meeting. The document contains detailed board decisions, voting results, and independent directors' opinions. It is not the annual report itself but a board meeting resolution announcement that references the annual report and other reports to be submitted to the shareholders' meeting. The document length is 8331 characters, which is substantial but the content is clearly a board meeting resolution announcement rather than the full annual report or financial statements. Therefore, the appropriate classification is Board/Management Information (MANG).
2019-03-11 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.